Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C4H5N4O3.Al.2HO |
| Molecular Weight | 218.1037 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[OH-].[OH-].[Al+3].NC(=O)NC1NC(=O)[N-]C1=O
InChI
InChIKey=NZILXMYBYNIXPF-UHFFFAOYSA-K
InChI=1S/C4H6N4O3.Al.2H2O/c5-3(10)6-1-2(9)8-4(11)7-1;;;/h1H,(H5,5,6,7,8,9,10,11);;2*1H2/q;+3;;/p-3
DescriptionSources: http://biotechnologia.pl/uploads/biotechnologia/product/leaflet/156476/info_20ALCLOXA.pdfhttp://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34714 | https://www.ncbi.nlm.nih.gov/pubmed/26620883Curator's Comment: description was created based on several sources, including:
http://tri-k.com/acloxa
Sources: http://biotechnologia.pl/uploads/biotechnologia/product/leaflet/156476/info_20ALCLOXA.pdfhttp://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34714 | https://www.ncbi.nlm.nih.gov/pubmed/26620883
Curator's Comment: description was created based on several sources, including:
http://tri-k.com/acloxa
Aldioxa is the generic name for the metal complex, dihydroxyaluminum allantoinate, which is hydrolyzed to allantoin and aluminium hydrate at the gastric mucosa. Aldioxa was approved in Japan to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. It was discovered, that aldioxa ameliorates delayed gastric emptying through its antagonistic activity on the α-2 adrenergic receptor. The most commonly reported adverse reactions include constipation.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1867 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | BODYGLIDE FOR HER Approved Usehelps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns. Launch Date2009 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
|||
| Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
|||
| Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.43 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
Antiperspirants, deodorants: Creams, spray, lossions: 0.25-0.5%
Baby products: creams; powders: 0.2-0.5%
Route of Administration:
Topical
In vitro Alcloxa inhibited formation and bacterial decomposition of pulverized human epidermal scales. The scales were obtained from patient with exfoliative dermatitis, characterized by a great deal of exudation. The scales were were pulverized in a Wiley mill, defatted with ether and suspended in a 0,2% Alcloxa solution.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29700
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8T66I31YNK
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | |||
|
DTXSID8057774
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | |||
|
100000087851
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | |||
|
226-964-4
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | |||
|
1634
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | |||
|
8T66I31YNK
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | |||
|
SUB05305MIG
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | |||
|
C76519
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | |||
|
23161
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | RxNorm | ||
|
5579-81-7
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | |||
|
C017231
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | |||
|
m1486
Created by
admin on Fri Dec 15 18:47:51 GMT 2023 , Edited by admin on Fri Dec 15 18:47:51 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
